Irrational prescription of surfactant replacement therapy in neonatal respiratory distress

PLoS One. 2022 Jun 16;17(6):e0268774. doi: 10.1371/journal.pone.0268774. eCollection 2022.

Abstract

Purpose: Respiratory distress is known as one of the leading causes of neonatal death. In recent decades, surfactant therapy has revolutionized respiratory failure. Since the implementation of the health system reform plan as well as the allocation of new financial resources for health system in Iran, the rate of irrational prescription has increased and prescription of surfactant for neonates, has raised unexpectedly, which is thought to be due to irrational prescriptions partly. The present study aimed to determine the rate of irrational prescription of surfactant for neonates with respiratory distress.

Methods: This research was a cross-sectional descriptive study, which was conducted retrospectively. In the current study, determining the rate of irrational prescription was done in terms of the surfactant prescription guideline. Finally, the medical data of 846 neonates who underwent surfactant therapy in Iran in 2018, were extracted from the information system of the Ministry of Health and the neonatal medical records.

Results: The results show that drug selection index, dose index, and time index were irrational for 14.30%, 27.42%, and 1.06% of neonates, respectively. Moreover, the total index of drug prescription, which is a combination of the above-mentioned three components, was found to be irrational for 31.47% of neonates.

Conclusions: The results of the present study are considered as a warning to providers and decision makers in the field of neonatal health to reduce irrational prescriptions of surfactant for neonates. This study suggests the use of educational interventions in order to reduce irrational prescriptions due to drug selection as well as the use of computer alert approaches in order to reduce irrational prescriptions due to wrong dose.

MeSH terms

  • Cross-Sectional Studies
  • Drug Prescriptions
  • Humans
  • Infant, Newborn
  • Infant, Newborn, Diseases* / drug therapy
  • Pulmonary Surfactants* / therapeutic use
  • Respiratory Distress Syndrome, Newborn* / drug therapy
  • Respiratory Insufficiency*
  • Retrospective Studies
  • Surface-Active Agents

Substances

  • Pulmonary Surfactants
  • Surface-Active Agents

Grants and funding

The authors received no specific funding for this work.